- Home
- RNA vs NBP Comparison
RNA vs NBP Comparison
Compare RNA & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | NBP |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.5M | 212.8M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNA | NBP |
|---|---|---|
| Price | $11.54 | $1.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 1 |
| Target Price | ★ $69.26 | $9.00 |
| AVG Volume (30 Days) | 162.8K | ★ 740.4K |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.12 | N/A |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.77 | $1.62 |
| 52 Week High | $73.06 | $5.19 |
Technical Indicators
Market Signals| Indicator | RNA | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 28.33 | 27.35 |
| Support Level | N/A | N/A |
| Resistance Level | $14.05 | $1.95 |
| Average True Range (ATR) | 0.50 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.38 | 4.00 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.